UBS analyst Eliana Merle raised the firm’s price target on Alnylam (ALNY) to $349 from $331 and keeps a Buy rating on the shares. The firm reiterates a top pick for Alnylam, saying the Q1 transthyretin amyloid cardiomyopathy early launch color highlights robust trends in access, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Market Position and Promising Growth with Buy Rating from Maury Raycroft
- Alnylam Pharma’s Strong Q1 Performance and Strategic Initiatives Drive Buy Rating with $336 Price Target
- Alnylam Pharmaceuticals Reports Strong Q1 2025 Growth
- Alnylam Pharmaceuticals Reports Strong Start to 2025
- Alnylam Pharma: Strong Strategic Positioning and Growth Prospects Justify Buy Rating